Pt Jayamas Medica Industri Tbk · IDX:OMED
Pt Jayamas Medica Industri Tbk — 3M 2026 Earnings Presentation
32 slides from Pt Jayamas Medica Industri Tbk's earnings presentation, May 2026
Slide 1: PT Jayamas Medica Industri Tbk (OMED IJ) Company Update 3M 2026
PT Jayamas Medica Industri Tbk (OMED IJ) Company Update 3M 2026 Mei 2026
Slide 2: Table of Contents
Table of Contents 1 Executive Summary 2 Company Overview 3 Business Overview 4 Key Investment Highlights 5 Growth Strategies 6 Financials & Operations 7 Corporate Highlights & Public Engagements
Slide 3: Executive Summary
EXECUTIVE SUMMARY
Slide 4: Executive Summary
Executive Summary PT Jayamas Medica Industri Tbk (OMED or “The Company”) founded in early 2000s. Since then, OMED has become a market leader in the Indonesian medical equipment and supplies market with a diverse product offering product portfolio consists of around 3,750 Active SKUs, supported by a
Slide 5: Company Overview
COMPANY OVERVIEW
Slide 6: Management Profile
Management Profile Board of Commissioners Dr. Yacobus Jemmy Hartanto, MPH Siane Soetanto David A. Worth President Commissioner Commissioner Independent Commissioner Years of Experience: 45 Years of Experience: 39 Years of Experience: 42 Universitas Mahidol Udayana University Dr. Jemmy Hartanto is th
Slide 7: Shareholders Structure
Shareholders Structure Treasury Dr. Jemmy Hartanto, MPH Siane Soetanto Public Shares Shares 50.00% 50.00% PT Intisumber Hasilsempurna – IHS 83.30% 0.94% 0.90% 14.67% 0,19% PT Jayamas Medica Industri Tbk – JMI (M edical Equipm ent & Supplies M anufacturer) *Listed Company 51.00% 99.00% PT Jayamas Wel
Slide 8: Key Milestones
Key Milestones Our Key Accomplishment Since 1992 1992 2000 2002 2006 2016 2022 2023 2024 - Present VENTURED KRIAN GROUND JOINT Total Area Distribution 2,200 sqm BREAKING VENTURES Business New Facility with Foreign Entities Batang, Central Java KRIAN EXPANSION Total Area EXPANDING 8,000 sqm Export to
Slide 9: Business Overview
BUSINESS OVERVIEW
Slide 10: Product Portfolio
Product Portfolio Sales by Products – 3M2026 Antiseptic & Dialysis 9.8% Includes liquid antiseptics 15.1% 12.4% and disinfectants, dialysis fluid, swabs and antiseptic wipes and gel 9.9% Diagnostic & Equipment 4.2% Includes thermometers, digital and manual tensimeters, weight scales and others 0.8%
Slide 11: Product Portfolio
Product Portfolio Sales by Products – 3M 2026 (Top 5 in Medical Disposable & Consumables) Infus Set & IV Underpad 7,1% 6,9% Syringe & Needles 19,1% Dlain 11,3% Others Gloves 27,8% 27,8%
Slide 12: Production Capacity and Utilization Rate
Production Capacity and Utilization Rate Production Capacity Utilization Product (Unit ‘000.000) Rate Product Category 2023 2024 2025 2025 Mask 550 599 599 60.1% Underpad 60 75 75 34.6% Disposable & Infusion Set and IV 50 50 50 58.0% Consumable Syringes and Needles 500 500 567 75.7% Foley Catheter 1
Slide 13: Production Facility
Production Facility KRIAN FACILITY MOJOAGUNG FACILITY BATANG FACILITY Krian Mojoagung Batang Year of Commencing 2002 2016 2024 Manufacturing Facilities 21,000 Sqm 67,846 Sqm 35,650 Sqm Location East Java Central Java ISO 13485 ISO 9001 ISO 13485 ISO 9001 Quality Quality Quality Quality ISO Managemen
Slide 14: National Distribution Center
National Distribution Center GRESIK, EAST JAVA PULO GADUNG, JAKARTA Gresik Jakarta Year of Commencing 2007 May 2026 (Estimated) Warehouse Size ±30,000 Sqm ±5,000 Sqm Location East Java Jakarta Coverage Area Eastern Part of Indonesia Western Part of Indonesia Source: Company
Slide 15: Prominent Customer Profile
Prominent Customer Profile Our Major Global Customer & Revenue Contribution Each Segment 3M 2026 PRIVATE 63.2% GOVERNMENT 36.2% 0.5% EXPORT OneMed’s Diversified Revenue Structure Reflects Low Concentration Risk and Resilient Business Fundamentals
Slide 16: Revenue Channels
Revenue Channels Sales by Brands Sales by Channel Merek OneMed Government Medical Retail Distributors bodies and Facilities customers entities Distributor with e- Supplies all product Catalogue permits are for hospitals able to on-sell to Supply of primarily government, while blood collection
Slide 17: Key Investment Highlight
KEY INVESTMENT HIGHLIGHT
Slide 18: Competitive Advantages
Competitive Advantages ONE STOP SHOPPING DIVERSE SALES CHANNELS 7 Product Categories Approximately 3,750 Active SKUs Retail Distributors Customers Export Medical Government Facilities Entities EXTENSIVE DISTRIBUTION MANUFACTURING FACILITIES 2 NDCs (1 Under Renovation) 13 Sales Offices >40% Locally M
Slide 19: Growth Strategies
GROWTH STRATEGIES
Slide 20: Growth Strategies
Growth Strategies IOL Export to Philippines New Store NDC Jakarta Several growth initiatives are underway to strengthen our market position, including the upcoming launch of locally manufactured IOL, exports to the Philippines, new retail store openings, and establishment of a new NDC in Jakarta. So
Slide 21: Large and Underserved Cataract Market: Indonesia
Large and Underserved Cataract Market : Indonesia WHAT IS CATARACT? GLOBAL CATARACT STATISTICS million CATARACT SURGICAL RATE (CSR) CATARACT IN INDONESIA > 8,000 ~ 7,000 + ~ 6,000 + Indonesia’s CSR is ~2–3x lower than regional peers, indicating significant ~ 2,300 underpenetration and limited surgic
Slide 22: IOL: Essential Solution for Cataract Treatment
IOL: Essential Solution for Cataract Treatment Launch Q4-2026 IOL AS THE SOLUTION IOL IMPLANT PROCEDURE IOL SIZE COMPARISON BEFORE VS AFTER IOL IMPLANT Diameter: 23 mm Overall diameter: 11.0 - 13.5 mm Optic diameter: 5.5 - 7.0 mm Lens thickness: 0.5 - 1.5 mm IMPLANTS Size comparison Dimensions in mm
Slide 23: Capacity and Market Expansion
Capacity and Market Expansion KRIAN BATANG MOJOAGUNG Estimated Budget Use of Proceed Business Expansion Plan Details (IDR Billion) (IDR Billion)* Construction of Buildings, Procurement of Production Machinery IDR 425 IDR 321 Machinery acquisition (Mojoagung & Krian) and Equipment National Distributi
Slide 24: Financial & Operations
FINANCIAL & OPERATIONS
Slide 25: Financial Overview
Financial Overview Revenue (In Billion Rupiah) EBITDA (In Billion Rupiah) Net Profit (In Billion Rupiah) 2,064 1,886 1,737 21.6% 22.4% 22.6% 23.0% 17.2% 17.9% 17.3% 20.7% 16.8% 31.4% 14.9% 461.9 324.0 368.9 572.2 359.5 407.3 259.4 436.3 98.4 131.4 73.1 99.0 2023 2024 2025 1Q25 1Q26 2023 2024 2025 1Q
Slide 26: Operational Highlight
Operational Highlight Volume Price Sales (in thousand units) 3M2025 3M2026 YoY (in IDR) 3M2025 3M2026 YoY (in thousand IDR) 3M2025 3M2026 YoY Average Sales Volume Selling Price Sales Value Disposable & Disposable & Disposable & 370,758 679,253 83.2% 602 403 -33.1% 223,246,225 273,722,113 22.6% Consu
Slide 27: Key Performance Ratios
Key Performance Ratios Key Ratios 2022 2023 2024 2025 1Q 2025 1Q 2026 Profitability Ratios Revenue Growth (YoY) -21.9% -0.1% 8.6% 9.4% 2.1% 31.2% Gross Profit Margin 35.1% 31.8% 33.1% 34.8% 33.7% 36.0% EBITDA Margin 25.0% 23.1% 21.6% 22.4% 22.6% 23.0% Net Profit Margin 16.8% 14.9% 17.2% 17.8% 16.8%
Slide 28: 3M 2026 Financial Highlights
3M 2026 Financial Highlights Strong Start to 2026 with Accelerated Growth and Improving Profitability 1. Revenue recorded solid growth of 31.1% YoY to IDR 572.2 billion, driven by significant volume expansion of 54.1% across key segments 2. Volume growth broad-based across portfolio, led by: • Biote
Slide 29: Corporate Highlights & Public Engagements
CORPORATE HIGHLIGHTS & PUBLIC ENGAGEMENTS
Slide 30: Corporate Highlights & Public Engagements
Corporate Highlights & Public Engagements Healthcare Forum PwC Indonesia: Public Education: Behind The Chart Podcast: Innovative strategies to improve hospital OMED X Magister Kenotariatan UBAYA OMED X YB Sekuritas operations and patient experience Source: Company’s Social Media
Slide 31: Thank You
THANK YOU PT Jayamas Medica Industri Tbk (OMED IJ)
Slide 32: Contact Us
CONTACT US ir@onemed.co.id https://www.tokopedia.com/onemed corporate.secretary@onemed.co.id https://www.onemed.co.id/ https://shopee.co.id/onemed https://omed.idx
PT Jayamas Medica Industri — 3M 2026 Earnings Presentation on 6ix